Disruption of protein-protein interaction hotspots in the C-terminal domain of MLH1 confers mismatch repair deficiency [0.03%]
MLH1羧基末端结构域互作热点的破坏导致错配修复缺陷
Keri M Fishwick,Diego Gomez Vieito,Giada Greco et al.
Keri M Fishwick et al.
MutLα, a heterodimer of MLH1 and PMS2, plays a key role in DNA mismatch repair (MMR), which maintains genomic stability by correcting replication errors. Loss of MLH1 function causes MMR deficiency (MMRd), leading to elevated mutation rate...
IGF1R-targeted delivery of a bridged nucleic acid oligonucleotide-peptide conjugate for microRNA-21 inhibition in triple-negative breast cancer [0.03%]
针对IGF1R递送桥连核酸寡核苷酸-肽缀合物以抑制三阴性乳腺癌中microRNA-21活性
Yuanyuan Jin,Vilas S Desai,Jason D Mazzaroth et al.
Yuanyuan Jin et al.
Triple-negative breast cancer (TNBC), defined by the absence of ER, PR, and Her2, impacts over 46 000 U.S. women annually, disproportionately affecting minority ethnic groups and individuals with BRCA mutations. Despite advancements such as...
Uracil-DNA glycosylase deficiency is associated with repressed tumor cell-intrinsic inflammatory signaling and altered sensitivity to exogenous interferons [0.03%]
尿嘧啶-DNA糖基化酶缺陷与抑制的肿瘤细胞固有炎症信号和对炎性因子敏感性的改变相关
Frank P Vendetti,Pinakin Pandya,Carina R Sclafani et al.
Frank P Vendetti et al.
2'-deoxyuridine (dU) is a common DNA lesion resulting from cytosine deamination and from dUMP incorporation by DNA polymerases, both of which are prevalent in cancer. The primary mechanism that repairs dU lesions in genomic DNA is base exci...
The alternative lengthening of telomeres pathway through a DNA repair lens: mechanism and therapeutic opportunities [0.03%]
通过DNA修复机制研究替代端粒延长途径：作用机制及治疗机会
Daniela Muoio,Elise Fouquerel
Daniela Muoio
The alternative lengthening of telomeres (ALT) pathway is a telomerase-independent telomere maintenance mechanism leveraged by a subset of human cancers. In these tumors, telomere DNA synthesis is achieved via homologous recombination-based...
Contrasting roles of APE1 and APE2 in genome maintenance, cancer development, and therapeutic targeting [0.03%]
APE1和APE2在基因组维护、癌症发展和治疗靶点选择中的不同作用
Aman Sharma,Helen E Grimsley,Katharine Courtemanche et al.
Aman Sharma et al.
Apurinic/apyrimidinic endonucleases - APE1 and APE2 are central to genome maintenance and the cellular DNA damage response, with expanding relevance in cancer biology. APE1 is the primary endonuclease in base excision repair and functions a...
Aninda Dey,Ryan P Barnes
Aninda Dey
Cancer cells display dysregulated metabolic programs, which result in excessive reactive oxygen species (ROS) leading to oxidative stress. ROS reaction with macromolecules, including proteins, lipids, and nucleic acids, can result in damagi...
Base excision repair within structure-forming repeat sequences and its impact on cancer and other diseases [0.03%]
结构形成重复序列中的碱基切除修复及其对癌症和其他疾病的影响
Carson B Cohen,Millie C Coombes,Christopher P Merlo et al.
Carson B Cohen et al.
Oxidative DNA damage is a major driver of genome instability and human disease. Among the various types of oxidative DNA base lesions, 8-oxo-7,8-dihydroguanine (8oxoG) is particularly prevalent due to guanine's low oxidation potential and t...
Natalie Rudolfova,Alexander Myhr Skjetne,Nicola P Montaldo et al.
Natalie Rudolfova et al.
Small base lesions in DNA are primarily repaired through the base excision repair pathway, which is initiated by DNA glycosylases. This review focuses on single-strand selective monofunctional uracil-DNA glycosylase (SMUG1), an enzyme whose...
A common food mutagen promotes intestinal carcinogenesis by multiple mechanisms in mouse models of Lynch syndrome [0.03%]
一种常见食物致_mutagen_通过多种机制促进林奇综合征小鼠模型肠道肿瘤发生发展
Emily Rayner,Anastasia Tsaalbi-Shtylik,Lemelinda Marques et al.
Emily Rayner et al.
Lynch syndrome (LS) is a colorectal cancer predisposition caused by an inherited heterozygous defect in any of four DNA mismatch repair (MMR) genes. MMR prevents nucleotide substitution mutations by correcting errors of replication opposite...
PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7 [0.03%]
IDH1突变癌中由于端粒保护因子53BP1和REV7丢失介导的PARP抑制剂耐药性
Daniel Andrés Colón-Ríos,Jonathan Dow,Adam Krysztofiak et al.
Daniel Andrés Colón-Ríos et al.
Acquired resistance presents a major challenge for targeted therapies, with initially responsive tumors eventually reverting underlying vulnerabilities. Our group recently reported that cancers harboring isocitrate dehydrogenase 1/2 (IDH1/2...